Correction To Private Placement Announcement of October 9, 2009
The change is a result of subscriptions by six directors and officers of Sonomax for an aggregate of 7,421,668 shares and warrants in the private placement, of which 4,643,334 shares were issued at a price of
Each of the 18,573,334 shares issued at a price of
As previously announced, Sonomax will use the proceeds from the private placement primarily to fund its continuing development of its self-fit custom expansion earpieces, as well as for the pre-launch sales and marketing initiatives scheduled for later this year.
The shares and warrants issued in the private placement are subject to a "hold period" expiring on
About the New Sonomax:
Sonomax is an R&D and licensing company of in-ear technologies. The Company's patented instant custom-fitting earpieces deliver the most comfortable sound-enhancing earpieces in the world. This unique technology enables a wide range of applications such as earphones for the music and gaming markets, hearing protection for military and industrial applications, affordable hearing aids and the ever-expanding Bluetooth(TM) headset market.
This news release contains certain forward-looking statements that reflect the current views and/or expectations of Sonomax Hearing Healthcare Inc. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
%SEDAR: 00013736E
For further information: Nick Laperle, President and CEO, Sonomax Hearing Healthcare Inc., (514) 932-2674, [email protected]
Share this article